JP2022519377A5 - - Google Patents
Info
- Publication number
- JP2022519377A5 JP2022519377A5 JP2021546223A JP2021546223A JP2022519377A5 JP 2022519377 A5 JP2022519377 A5 JP 2022519377A5 JP 2021546223 A JP2021546223 A JP 2021546223A JP 2021546223 A JP2021546223 A JP 2021546223A JP 2022519377 A5 JP2022519377 A5 JP 2022519377A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- cargo protein
- targeted cargo
- cancer
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802652P | 2019-02-07 | 2019-02-07 | |
| US62/802,652 | 2019-02-07 | ||
| PCT/CA2020/000013 WO2020160639A1 (en) | 2019-02-07 | 2020-02-07 | Il-4r as a biomarker in cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519377A JP2022519377A (ja) | 2022-03-23 |
| JP2022519377A5 true JP2022519377A5 (https=) | 2023-02-14 |
Family
ID=71946943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546223A Withdrawn JP2022519377A (ja) | 2019-02-07 | 2020-02-07 | がんのバイオマーカーとしてのｉｌ－４ｒ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220347268A1 (https=) |
| EP (1) | EP3921637A1 (https=) |
| JP (1) | JP2022519377A (https=) |
| CN (1) | CN113728232A (https=) |
| CA (1) | CA3129200A1 (https=) |
| WO (1) | WO2020160639A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104619334A (zh) | 2012-08-09 | 2015-05-13 | 利兰斯坦福初级大学董事会 | 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 |
| EP3049526B1 (en) | 2013-09-24 | 2021-02-24 | Medicenna Therapeutics, Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| CN111201035A (zh) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
| EP3694558B1 (en) | 2017-10-10 | 2024-04-10 | Medicenna Therapeutics Inc. | Il-4-fusion formulations for treatment of central nervous system (cns) tumors |
| US12590133B2 (en) | 2018-06-01 | 2026-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| EP4225377A4 (en) * | 2020-10-12 | 2024-11-27 | Medicenna Therapeutics, Inc. | COMBINATION THERAPY WITH MDNS55 AND A VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A) |
| CN118146395A (zh) * | 2021-02-08 | 2024-06-07 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| US20240239857A1 (en) * | 2021-05-19 | 2024-07-18 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Il-13ralpha2 targeted immunotoxins and methods of use |
| WO2023102193A1 (en) * | 2021-12-02 | 2023-06-08 | Ohio State Innovation Foundation | Methods and compositions related to inflammatory gene panel |
| WO2024214083A1 (en) * | 2023-04-14 | 2024-10-17 | Medicenna Therapeutics Inc. | Use of immunomodulation methods in combination with cytokine fusions for disease treatment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010031185A1 (en) * | 2008-09-19 | 2010-03-25 | Protox Therapeutics Inc. | Treating cancer stem cells using targeted cargo proteins |
| TWI397428B (zh) * | 2009-12-29 | 2013-06-01 | 財團法人工業技術研究院 | 標的第四介白素受體之傳輸系統 |
| US10849960B2 (en) * | 2017-09-08 | 2020-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer |
| EP3694558B1 (en) * | 2017-10-10 | 2024-04-10 | Medicenna Therapeutics Inc. | Il-4-fusion formulations for treatment of central nervous system (cns) tumors |
-
2020
- 2020-02-07 CN CN202080024878.2A patent/CN113728232A/zh active Pending
- 2020-02-07 US US17/428,697 patent/US20220347268A1/en not_active Abandoned
- 2020-02-07 EP EP20753029.6A patent/EP3921637A1/en not_active Withdrawn
- 2020-02-07 WO PCT/CA2020/000013 patent/WO2020160639A1/en not_active Ceased
- 2020-02-07 JP JP2021546223A patent/JP2022519377A/ja not_active Withdrawn
- 2020-02-07 CA CA3129200A patent/CA3129200A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519377A5 (https=) | ||
| Xiao et al. | Interleukin-6 mediated inflammasome activation promotes oral squamous cell carcinoma progression via JAK2/STAT3/Sox4/NLRP3 signaling pathway | |
| Ishiuchi et al. | Hypoxia-preconditioned mesenchymal stem cells prevent renal fibrosis and inflammation in ischemia-reperfusion rats | |
| Lee et al. | IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses | |
| Chen et al. | Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy | |
| Lau et al. | An Akt/hypoxia-inducible factor-1α/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells | |
| Xu et al. | Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor β signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model | |
| Chen et al. | Enhancing aortic valve drug delivery with PAR2-targeting magnetic nano-cargoes for calcification alleviation | |
| Stoeltzing et al. | Role of hypoxia-inducible factor 1α in gastric cancer cell growth, angiogenesis, and vessel maturation | |
| Daldrup-Link et al. | MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles | |
| Yuan et al. | Intrahepatic cholangiocarcinoma induced M2-polarized tumor-associated macrophages facilitate tumor growth and invasiveness | |
| Goodwin et al. | Local and transient gene expression primes the liver to resist cancer metastasis | |
| ES2727450T3 (es) | Diagnóstico y terapia de trastornos autoinmunes inflamatorios mediados por anticuerpos | |
| Vandergrift et al. | Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas | |
| Siclari et al. | Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis | |
| Onishi et al. | Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma | |
| Lee et al. | An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone | |
| JP2014504149A (ja) | 治療と併用する癌画像診断：セラノスティックス | |
| Julku et al. | Brain pharmacokinetics of mono-and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis | |
| Mohr et al. | Enhanced colorectal cancer metastases in the alcohol-injured liver | |
| Xiong et al. | Exosomal IL-8 derived from Lung Cancer and Colon Cancer cells induced adipocyte atrophy via NF-κB signaling pathway | |
| Vannucci et al. | In vivo targeting of cutaneous melanoma using an melanoma stimulating hormone-engineered human protein cage with fluorophore and magnetic resonance imaging tracers | |
| Falgàs et al. | Specific cytotoxic effect of an auristatin nanoconjugate towards CXCR4+ diffuse large b-cell lymphoma cells | |
| Liu et al. | Cancer-associated fibroblasts promote malignant phenotypes of prostate cancer cells via autophagy: cancer-associated fibroblasts promote prostate cancer development | |
| Qin et al. | Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme |